FDA Okays Venclexta Plus Gazyva for Previously Untreated Chronic Lymphocytic Leukaemia FDA Okays Venclexta Plus Gazyva for Previously Untreated Chronic Lymphocytic Leukaemia
Roche said on Thursday that the U.S. Food and Drug Administration had approved Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) for the treatment of people with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 17, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Approves Venetoclax for Chronic Lymphocytic Leukemia
In randomized trial, drug demonstrated statistically significant improvement in progression - free survival (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 17, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news

FDA Approves Venetoclax for Chronic, Small Lymphocytic Leukemia
THURSDAY, May 16, 2019 -- Venetoclax (VENCLEXTA) has been approved to treat adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, the U.S. Food and Drug Administration announced yesterday. Data from CLL14, a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 16, 2019 Category: Pharmaceuticals Source Type: news

Roche: FDA approves drug combo Venclexta plus Gazyva for previously untreated chronic lymphocytic leukemia
Roche said on Thursday that the U.S. Food and Drug Administration had approved a treatment using its drugs Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukemia. (Source: Reuters: Health)
Source: Reuters: Health - May 16, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia
Roche today announced that the US Food and Drug Administration (FDA) has approved Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) for the treatment of people with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). (Source: Roche Media News)
Source: Roche Media News - May 16, 2019 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia
Roche today announced that the US Food and Drug Administration (FDA) has approved Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) for the treatment of people with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). (Source: Roche Investor Update)
Source: Roche Investor Update - May 16, 2019 Category: Pharmaceuticals Source Type: news

Researchers pinpoint why lymphoma patients may become resistant to specific therapy
(H. Lee Moffitt Cancer Center& Research Institute) Researchers from Moffitt Cancer Center and Dana-Farber Cancer Institute have discovered a mechanism of drug resistance to Venetoclax ® , also known as ABT-199, a BCL-2 targeting drug commonly used to treat chronic lymphocytic leukemia and acute myeloid leukemia. Their findings, published in the journal Cancer Cell, also suggest a possible co-treatment strategy to overcome this resistance. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 15, 2019 Category: Cancer & Oncology Source Type: news

Medical trials at Aurora Research Institute uncover lifesaving news for leukemia patients
A prolonged life and fewer side effects are among the benefits for leukemia patients on a specific drug regimen, according to two new clinical trials. The breakthrough findings are expected to immediately change the treatment for patients with leukemia. Both trials Aurora Research Institute studied the anticancer drug called ibrutinib for treating chronic lymphocytic leukemia (CLL). “CLL is the most common leukemia in adults in Western count ries,” said Dr. Rubina Qamar, the principal investigator… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 29, 2019 Category: Biotechnology Authors: Advocate Aurora Health Source Type: news

Medical trials at Aurora Research Institute uncover lifesaving news for leukemia patients
A prolonged life and fewer side effects are among the benefits for leukemia patients on a specific drug regimen, according to two new clinical trials. The breakthrough findings are expected to immediately change the treatment for patients with leukemia. Both trials Aurora Research Institute studied the anticancer drug called ibrutinib for treating chronic lymphocytic leukemia (CLL). “CLL is the most common leukemia in adults in Western count ries,” said Dr. Rubina Qamar, the principal investigator… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 29, 2019 Category: American Health Authors: Advocate Aurora Health Source Type: news

Reasons for TKI Discontinuation ID'd in Chronic Myeloid Leukemia
TUESDAY, April 16, 2019 -- For patients with chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) therapy can be safely discontinued and yields high rates of treatment-free remission (TFR), according to a study published online March 16... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 16, 2019 Category: Pharmaceuticals Source Type: news

How 'sleeper cell' cancer stem cells are maintained in chronic myelogenous leukemia
(University of Alabama at Birmingham) Even when chronic myelogenous leukemia is in remission, 'sleeper cell,' quiescent leukemic stem cells are maintained in microenvironments in the bone marrow. This maintenance is poorly understood. Researchers now describe how niche-specific expression of a particular chemokine by a particular type of bone marrow cell controls quiescence of these treatment-resistant leukemic stem cells. The chemokine is CXCL12, and the particular bone marrow cells expressing it are mesenchymal stromal cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 21, 2019 Category: Cancer & Oncology Source Type: news

Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
Roche today announced the submission of a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Venclexta ® (venetoclax) in combination with Gazyva® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions. (Source: Roche Media News)
Source: Roche Media News - March 7, 2019 Category: Pharmaceuticals Source Type: news

Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
Roche today announced the submission of a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Venclexta ® (venetoclax) in combination with Gazyva® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions. (Source: Roche Investor Update)
Source: Roche Investor Update - March 7, 2019 Category: Pharmaceuticals Source Type: news

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses... (Source: The Scientist)
Source: The Scientist - February 19, 2019 Category: Science Tags: The Scientist The Marketplace Source Type: news

Some Cancers Are Rising in Young People. Scientists Think They Know Why
The rates of new cancer cases and cancer deaths have fallen in the U.S. over the past few decades. But certain cancers are becoming more common among younger Americans, and researchers think obesity may be to blame, finds a new report from the American Cancer Society and the National Cancer Institute. Rates of six different cancers that are associated with obesity increased among adults ages 25-49 between 1995 and 2014, according to the research, which was published in the journal Lancet Public Health and based on information in the Cancer in North America database. These cancers include multiple myeloma, colorectal, endom...
Source: TIME: Health - February 4, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cancer healthytime Source Type: news

Some Cancers Are Rising in Millennials. Obesity Might Be the Reason Why
The rates of new cancer cases and cancer deaths have fallen in the U.S. over the past few decades. But certain cancers are becoming more common among younger Americans, and researchers think obesity may be to blame, finds a new report from the American Cancer Society and the National Cancer Institute. Obesity rates have been rising across age groups for years. According to the latest federal numbers, almost 36% of American adults ages 20-39 are obese, and that number may soon be even higher. Recent research suggests that if obesity trends continue, 57% of children in the U.S. will be obese by the time they turn 35. Rates ...
Source: TIME: Health - February 4, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cancer healthytime Source Type: news

Some Cancers Are Rising in Millennials. Obesity Might Be Why
The rates of new cancer cases and cancer deaths have fallen in the U.S. over the past few decades. But certain cancers are becoming more common among younger Americans, and researchers think obesity may be to blame, finds a new report from the American Cancer Society and the National Cancer Institute. Obesity rates have been rising across age groups for years. According to the latest federal numbers, almost 36% of American adults ages 20-39 are obese, and that number may soon be even higher. Recent research suggests that if obesity trends continue, 57% of children in the U.S. will be obese by the time they turn 35. Rates ...
Source: TIME: Health - February 4, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Cancer healthytime Source Type: news

FDA Approves Imbruvica (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Na ïve Patients with Chronic Lymphocytic Leukemia
HORSHAM, Pa., Jan. 28, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Imbruvica (ibrutinib) in combination with obinutuzumab in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 28, 2019 Category: Drugs & Pharmacology Source Type: news

FDA Approves First Nonchemo Regimen for CLL/SLL FDA Approves First Nonchemo Regimen for CLL/SLL
This is the first approval of a nonchemotherapy combination for untreated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

U.S. FDA Approves IMBRUVICA ® (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
(Source: Johnson and Johnson)
Source: Johnson and Johnson - January 28, 2019 Category: Pharmaceuticals Source Type: news

U.S. FDA Approves IMBRUVICA(R) (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Patients treated with IMBRUVICA plus obinutuzumab experienced a 77 percent reduction in risk of progression or death compared to chlorambucil plus obinutuzumab Approval broadens the label in frontline CLL and represents the tenth FDA approval for IMBRUV... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson & Johnson, IMBRUVICA, ibrutinib (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 28, 2019 Category: Pharmaceuticals Source Type: news

New treatment for adults with chronic lymphocytic leukaemia
NICE is recommending venetoclax with rituximab for adults with relapsed or refractory chronic lymphocytic leukaemia. Thousands of patients should benefit, NICE says. (Source: NHS Networks)
Source: NHS Networks - January 23, 2019 Category: UK Health Source Type: news

Patients with chronic myeloid leukemia can manage their anxiety with bitter orange essential oil
(Natural News) Patients with chronic myeloid leukemia, who often suffer from anxiety, may find relief in bitter orange (Citrus aurantium L.) essential oil. A study published in the journal Phytotherapy Research reported that breathing in bitter orange essential oil could reduce anxiety in people with chronic myeloid leukemia, suggesting that it has potential use as... (Source: NaturalNews.com)
Source: NaturalNews.com - January 21, 2019 Category: Consumer Health News Source Type: news

New leukemia drug is more effective and easier to use
(Loyola University Health System) A landmark study co-authored by a Loyola Medicine oncologist has found that a newer targeted drug is significantly more effective than standard therapy for treating elderly patients with chronic lymphocytic leukemia (CLL). The drug is taken as a pill once a day -- much more convenient than the standard treatment requiring the patient to come in three times a month for infusions and an injection. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2019 Category: International Medicine & Public Health Source Type: news

Top Discoveries in Chronic Lymphocytic Leukemia at ASH 2018
In an interview withCancer Network, Brad S. Kahl, MD, weighs in on the top CLL research presented at ASH 2018 in San Diego. (Source: CancerNetwork)
Source: CancerNetwork - December 19, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

MRD Effective as Surrogate Endpoint in CLL?
A patient ’s minimal residual disease status may serve as a surrogate marker for outcome in clinical trials of chronic lymphocytic leukemia in patients with comorbidities. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Testing and Treatment Patterns Rapidly Changing in CLL
Testing patterns associated with the diagnosis and treatment of chronic lymphocytic leukemia have changed rapidly during the last decade. (Source: CancerNetwork)
Source: CancerNetwork - December 12, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

LZTR1 is a regulator of RAS ubiquitination and signaling
In genetic screens aimed at understanding drug resistance mechanisms in chronic myeloid leukemia cells, inactivation of the cullin 3 adapter protein-encoding leucine zipper-like transcription regulator 1 (LZTR1) gene led to enhanced mitogen-activated protein kinase (MAPK) pathway activity and reduced sensitivity to tyrosine kinase inhibitors. Knockdown of the Drosophila LZTR1 ortholog CG3711 resulted in a Ras-dependent gain-of-function phenotype. Endogenous human LZTR1 associates with the main RAS isoforms. Inactivation of LZTR1 led to decreased ubiquitination and enhanced plasma membrane localization of endogenous KRAS (V...
Source: ScienceNOW - December 6, 2018 Category: Science Authors: Bigenzahn, J. W., Collu, G. M., Kartnig, F., Pieraks, M., Vladimer, G. I., Heinz, L. X., Sedlyarov, V., Schischlik, F., Fauster, A., Rebsamen, M., Parapatics, K., Blomen, V. A., Müller, A. C., Winter, G. E., Kralovics, R., Brummelkamp, T. R., Mlod Tags: Cell Biology, Medicine, Diseases reports Source Type: news

New Phase 3 Study Findings Show IMBRUVICA ® (ibrutinib) Plus Rituximab Significantly Improved Survival Compared to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Previously Untreated Patients Aged 70 or Younger with Chronic Lymphocytic Leukemia
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 4, 2018 Category: Pharmaceuticals Source Type: news

Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia
Chronic lymphocytic leukemia is one of the most common types of leukemia in adults typically occurring during or after middle age and rarely occurring in individuals under the age of 40. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - December 4, 2018 Category: American Health Source Type: news

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
Roche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions. (Source: Roche Media News)
Source: Roche Media News - December 4, 2018 Category: Pharmaceuticals Source Type: news

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
Roche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions. (Source: Roche Investor Update)
Source: Roche Investor Update - December 4, 2018 Category: Pharmaceuticals Source Type: news

Ibrutinib Alone for Older Patients With Untreated CLL Ibrutinib Alone for Older Patients With Untreated CLL
Ibrutinib alone and ibrutinib with rituximab were both superior to the bendamustine – rituximab combination for older patients with chronic lymphocytic leukemia (CLL).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

IMBRUVICA ® (ibrutinib) Plus Obinutuzumab Showed Significant Improvement in Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 3, 2018 Category: Pharmaceuticals Source Type: news

ASH: Ibrutinib Tops Bendamustine & #43; Rituximab for CLL
MONDAY, Dec. 3, 2018 -- For older patients with untreated chronic lymphocytic leukemia (CLL), treatment with ibrutinib alone or in combination with rituximab is associated with improved progression-free survival versus bendamustine plus rituximab,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Experts present new recommendations on 'overlapping' type of leukemia
(Wolters Kluwer Health) Chronic myelomonocytic leukemia (CMML) is a rare disease with overlapping features of two categories of bone marrow and blood cell disorders that poses challenges in clinical management. Joint recommendations on diagnosis and treatment of CMML from two European specialty societies were published today in HemaSphere, the official journal of the European Hematology Association (EHA). The journal is published in the Lippincott portfolio by Wolters Kluwer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 30, 2018 Category: International Medicine & Public Health Source Type: news

For Chronic Leukemia Patients, the News Just Got Even Better
Several chronic lymphocytic leukemia (CLL) patients at the Wilmot Cancer Institute took part in two groundbreaking, nationwide phase 3 studies that are changing the way doctors treat the disease. The positive results are being reported this weekend at the 2018 American Society of Hematology (ASH) annual meeting — and will immediately impact CLL patients in the Rochester region and across the U.S., said Paul Barr, M.D., director of Wilmot’s Clinical Trials Office. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - November 29, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

FDA approves new treatment for patients with acute myeloid leukemia
The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy. (Source: World Pharma News)
Source: World Pharma News - November 22, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA approves new treatment for patients with acute myeloid leukemia
The FDA approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy. (Source: Food and Drug Administration)
Source: Food and Drug Administration - November 21, 2018 Category: American Health Source Type: news

Leukemic Arthritis and Severe Hypercalcemia in CML Leukemic Arthritis and Severe Hypercalcemia in CML
This case demonstrates potential manifestations of leukemic arthritis and severe hypercalcemia in patients with advanced chronic myeloid leukemia.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 7, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

AbbVie Receives European Commission Approval of VENCLYXTO(R) (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
The approval is based on the MURANO Phase 3 clinical trial, in which VENCLYXTO® plus rituximab reduced the risk of disease progression or death by 83 percent and overall survival was prolonged compared to bendamustine in combination with rituximab, a s... Biopharmaceuticals, Oncology, Regulatory AbbVie, VENCLYXTO, venetoclax, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 1, 2018 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities
Roche announced today that the randomised phase III CLL14 study, which evaluated fixed-duration Venclexta ®/Venclyxto® (venetoclax) in combination with Gazyva®/Gazyvaro® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death (PFS; as assessed by investigator) compared to standard-of-care Gazyva/Gazyvaro plus chlorambucil. The results showed that no new safety signals or increase in known toxicities of Venclexta/Venclyxto or Ga...
Source: Roche Media News - November 1, 2018 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities
Roche announced today that the randomised phase III CLL14 study, which evaluated fixed-duration Venclexta ®/Venclyxto® (venetoclax) in combination with Gazyva®/Gazyvaro® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death (PFS; as assessed by investigator) compared to standard-of-care Gazyva/Gazyvaro plus chlorambucil. The results showed that no new safety signals or increase in known toxicities of Venclexta/Venclyxto or Ga...
Source: Roche Investor Update - November 1, 2018 Category: Pharmaceuticals Source Type: news

Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Roche today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with MabThera® (rituximab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. (Source: Roche Media News)
Source: Roche Media News - November 1, 2018 Category: Pharmaceuticals Source Type: news

Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Roche today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with MabThera® (rituximab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - November 1, 2018 Category: Pharmaceuticals Source Type: news

NICE rejects AbbVie leukemia drug over price
NICE gave a negative opinion on AbbVie ’s Venclyxta in combination with Roche’s Rituxan, for treating relapsed or refractory chronic lymphocytic leukaemia in adults. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 26, 2018 Category: Pharmaceuticals Source Type: news

Researchers in Barcelona awarded with one of the most prestigious EU grants to unravel CLL
(Center for Genomic Regulation) The European Research Council today announced the results of the 2018 ERC Synergy Grants Call. A project, the BCLL@las, of four research groups from the Centro Nacional de An á lisis Gen ó mico of the Centre for Genomic Regulation, and the Institut d'Investigacions Biom è diques August Pi i Sunyer have received this prestigious grant to unravel the genomics and epigenomics of chronic lymphocytic leukemia at unprecedented resolution using single-cell analysis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 26, 2018 Category: Cancer & Oncology Source Type: news

AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
If granted, IMBRUVICA plus obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for first-line CLL treatment The submission is based on positive results from the Phase 3 iLLUMINATE (PCYC-1130) trial, which sho... Biopharmaceuticals, Oncology, FDA AbbVie, IMBRUVICA, ibrutinib, obinutuzumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 17, 2018 Category: Pharmaceuticals Source Type: news

Duvelisib Promising for Chronic Lymphocytic Leukemia, SLL
Duvelisib extended progression - free survival to 13.3 months versus 9.9 months for ofatumumab (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 10, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news

Duvelisib Promising for Chronic Lymphocytic Leukemia, SLL
WEDNESDAY, Oct. 10, 2018 -- For patients with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), the oral, dual inhibitor of phosphoinositide 3-kinase- δ and -γ, duvelisib, seems effective, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 10, 2018 Category: Pharmaceuticals Source Type: news